Abstract
VACCINES are available to act against many of the diseases caused by enveloped viruses. The efficacy and safety of the vaccines depend on the method used to convert the virus into a vaccine. Whole viruses that have been attenuated or killed are effective, but both of these types of vaccines may give rise to undesirable side effects which limit their use1–3. These complications are caused by the virus genome or by toxic components in the virus preparations. The components that give rise to the side effects do not seem to be those that are important for evoking protective immunity and it is therefore possible to prepare vaccines which contain only the necessary antigenic subunits, which for the enveloped viruses are the spike glycoproteins4–7. But although subunit vaccines have proved safer than whole virus vaccines, their immunogenicity is generally lower8,9, perhaps because the form in which the proteins are presented in the vaccines is not optimal for eliciting a strong immune response10. In support of that explanation, we present here evidence that a lethal infection of mice with Semliki Forest virus can be prevented by a single vaccination with the virus spike protein, provided it is presented as a micellar aggregate of the protein or as protein reconstituted into vesicles of egg lecithin. The monomer form of the spike protein solubilised with detergent is very much less effective.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Salk, J. & Slak, D. Science 195, 834–847 (1977).
Chanock, R. M. et al. in Viral Immunology and Immunopathology (ed. Notkins, A. L.) 308–316 (Academic, New York, 1975).
Ginsberg, H. S. in Viral Immunology and Immunopathology (ed. Notkins, A. L.) 317–326 (Academic, New York, 1975).
Bachmayer, H. in Influenza (ed. Salby, P.) 149–162 (Academic, New York, 1976).
Hunsmann, G., Moening, V. & Schäfer, W. Virology 66, 327–329 (1976).
Hillemann, M. R. Cancer Res. 36, 857–858 (1976).
Cappel, R. & De Cyper, F. Archs Virol. 50, 207–213 (1976).
Wright, P. F., Dolin, R. & La Montage, J. R. J. infect. Dis. 134, 633–638 (1976).
Gross, P. A. et al. J. infect. Dis. 136, 623–632 (1977).
Choppin, P. W. J. infect. Dis. 129, 765–767 (1974).
Bradish, C. J., Allner, B. & Maber, H. B. J. gen. Virol. 12, 141–160 (1971).
Mussgay, M. & Weiland, E. Intervirology 1, 259–277 (1973).
Simons, K., Garoff, H., Helenius, A. & Ziemiecki, A. in Frontiers of Physiochemical Biology (ed. Pullmann, B.) 387–407 (Academic, New York, 1978).
Simons, K., Garoff, H. & Helenius, A. in Membrane Proteins and their Interactions with Lipids (ed. Capaldi, R. A.) 207–234 (Marcel Decker, New York, 1977).
Helenius, A., Fries, E. & Kartenbeck, J. J. Cell Biol. 75, 866–880 (1977).
Simons, K., Helenius, A. & Garoff, H. J. molec. Biol. 80, 119–133 (1973).
Helenius, A. & Von Bonsdorff, C. H. Biochim. biophys. Acta 436, 895–899 (1976).
Almeida, J. D., Brand, C. M., Edwards, C. D. & Heath, T. D. Lancet ii, 899–901 (1975).
Simons, K., Helenius, A., Leonard, K., Sarvas, M. & Gething, M. J. Proc. natn. Acad. Sci. U.S.A. (in the press).
Bloom, B. R. & Rager-Zisman, B. in Viral Immunology and Immunopathology (ed. Notkins, A. L.) 113–133 (Academic, New York, 1975).
Schäfer, W. & Bolognesi, D. P. Contemp. Top. Immunobiol. 6, 127–167 (1977).
Brand, C. M. & Skehel, J. J. Nature new Biol. 238, 145–147 (1972).
Jennings, R., Brand, C. M., McLaren, C., Shephard, L. & Potter, C. W. Med. microbiol. Immunol. 160, 295–309 (1974).
Tyrrell, D. A. J. J. infect. Dis. 129, 766 (1974).
Nossal, G. J. V., Ada, G. L. & Austin, C. M. Austr. J. exp. Biol. med. Sci. 42, 283–294 (1964).
Unanue, E. R. Adv. Immun. 15, 95 (1972).
Neurath, A. R. & Rubin, B. A. in Monographs in Virology Vol. 4 (ed. Melnick, J. L.) 1–87 (Karger, Basel, 1971).
Batchelor, J. R., Welsh, K. J. & Burgos, H. Nature 273, 54–56 (1978).
Helenius, A. et al. Proc. natn. Acad. Sci. U.S.A. 75, 3846–3850 (1978).
Helenius, A. & Simons, K. Biochim. biophys. Acta 415, 29–79 (1975).
Tanford, C. & Reynolds, J. Biochim. biophys. Acta 457, 133–170 (1976).
Clarke, D. H. & Casals, J. Am. J. trop. Hyg. 7, 561–573 (1958).
Kääriäinen, L. & Gomatos, P. J. J. gen. Virol. 5, 251–265 (1969).
Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. J. biol. Chem. 193, 265–275 (1951).
Mayr, A., Bachmann, P. A., Bilbrack, B. & Wittmann, G. in Virologische Arbeitsmethoden Vol. 1, 39 (Gustav Fischer, Stuttgart, 1974).
Schmidt, N. J. in Diagnostic Procedures of Viral and Ricketsial Disease 3rd ed (eds Lennette, E. H. & Schmidt, N. J.) 78–176 (American Health Organisation, New York, 1964).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
MOREIN, B., HELENIUS, A., SIMONS, K. et al. Effective subunit vaccines against an enveloped animal virus. Nature 276, 715–718 (1978). https://doi.org/10.1038/276715a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/276715a0
This article is cited by
-
Precipitation reactions with Newcastle disease virus
Tropical Animal Health and Production (1995)
-
Semliki Forest Virus Expression System: Production of Conditionally Infectious Recombinant Particles
Nature Biotechnology (1993)
-
Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice
Cancer Immunology, Immunotherapy (1993)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
